This study provides the first in-vivo evidence to support the efficacy of MCL-1 BH3 mimetics [4, 43] in triple-negative breast cancer as single agents, and in combination with SRC family kinase inhibitors such as dasatinib. This evidence concerns the gene MCL1 and triple-negative breast carcinoma.